KALY - CBD Drug Patent BREAKOUT - 400% Run Potential From $0.01 To $0.04
New York, NY -- August 21, 2019 -- InvestorsHub NewsWire -- via www.nextbigticker.com -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) is coming out of the summer penny market doldrums and is now solidly back up over $0.01 after increasing in price well over 100% in the last 3 days of trading on massive volume. The company experienced over $1 million in stock trading yesterday. KALY has a 52-week high of nearly $0.04. With some consolidation today, it could be a good time to purchase KALY stock in advance of a potential run back to the nearly $0.04 52-week high. The company made a major CBD Drug announcement yesterday introducing its RespRx CBD Formulation for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). The announcement included an indication that two more major announcements are coming still this week – one tomorrow on Thursday, August 22nd and one on Friday August 23rd. Tomorrow the company plans to bring its financial reporting current and on Friday, the company plans to release more details on the patent application it filed on its RespRx drug and on the corresponding trademark application it filed.
Highlights from KALY’s RespRx CBD Formulation Annoucment Yesterday:
- KALY Develops COPD Treatment CBD Formulation from Its Patented Extraction Process
- KALY Files New Patent Application on Its CBD Formulation for the Treatment of COPD
- KALY Files Trademark Registration on RespRx Brand Name for COPD Treatment
- Market for COPD Treatment Anticipated to Reach $14 Billion
- KALY to File Up-To-Date Corporate Financials on Thursday This Week
- KALY to Publish RespRx Website with Patent and Trademark Details on Friday
Other cannabis stocks making news today include Hemp Naturals, Inc. (HPMM) ,American Premium Water Corp (HIPH) and Canbiola, Inc. (CANB)
NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.